Regencell Bioscience Limited (RGC) surged 28.59% in pre-market trading on Thursday, continuing its recent upward momentum. The stock's sharp rise reflects heightened investor optimism driven by significant developments in the brain-computer interface (BCI) sector.
The rally was catalyzed by Elon Musk's announcement that Neuralink will begin mass production of brain-computer interface devices in 2026. Additionally, China's Ministry of Industry and Information Technology issued supportive policies aimed at accelerating the commercialization of BCI technology. These developments have fueled expectations of rapid growth and industrialization in the sector, benefiting companies like Regencell Bioscience.
Comments